Thryv Therapeutics Begins Phase 2/3 Clinical Study for Long QT Syndrome with FDA Fast Track Designation
Thryv Therapeutics Inc. has commenced patient dosing in a Phase 2/3 clinical study, known as Wave II, to evaluate the safety and efficacy of THRV-1268 in patients with genetically confirmed Long QT Syndrome Type 2. This study is being conducted at leading inherited arrhythmia centers across the United States. The primary endpoint of the study will assess the change in QTcF over six hours, along with evaluations of cardiac rhythm stability, safety, and tolerability over a 12-week period. The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to THRV-1268 for the treatment of Long QT Syndrome Types 2 and 3, which supports expedited development of this investigational therapy. Professor Vasanth Vedantham, MD, PhD, at UCSF Health in San Francisco, initiated the first of fourteen patients planned in Part A of the study. 
